Filtrer vos résultats
- 3
- 1
- 4
- 4
- 1
- 1
- 2
- 4
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk WarningsJournal of Clinical Medicine, 2023, 12 (1), pp.207. ⟨10.3390/jcm12010207⟩
Article dans une revue
hal-03959526v1
|
||
|
Lack of Association between the TNFAIP3 Rs2230926 Variant and Rheumatoid Arthritis-Associated Lymphoma.Joint Bone Spine, 2022, 89 (5), pp.105390. ⟨10.1016/j.jbspin.2022.105390⟩
Article dans une revue
hal-03792023v1
|
||
Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumabJoint Bone Spine, 2017, 84 (6), pp.685-691. ⟨10.1016/j.jbspin.2016.10.012⟩
Article dans une revue
hal-02005084v1
|
|||
Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based studyClinical Rheumatology, 2017, 36 (6), pp.1395-1400. ⟨10.1007/s10067-017-3587-8⟩
Article dans une revue
hal-03606093v1
|